Biomarqueurs prédictifs et nouvelles stratégies thérapeutiques en oncologie

Présentation du laboratoire

Cette unité travaille sur l'identification et la validation de nouvelles cibles thérapeutiques ainsi que des prédicteurs moléculaires en oncologie. Ce travail est basé sur le principe de la caractérisation moléculaire à haut débit afin de conduire à l'identification de cibles thérapeutiques. La mission de cette équipe consiste à transférer les connaissances moléculaires à la pratique clinique, et d'utiliser des échantillons de patients en tant que source d'hypothèses de recherche. L'un des objectifs est la mise en place d'essais cliniques afin de tester des biomarqueurs, le second est le pilotage de projet ou en support d'autres unités effectuant de la recherche fondamentale pour le passage en recherche translationnelle. Le développement des technologies et des outils bioinformatiques pour la recherche translationnelle fait partie des objectifs de cette unité.

Les 20 dernières publications

Titre Auteurs Date de publication Source
BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation Sophie Postel-Vinay 01/12/2019 Nature Communications
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary Alexandra Leary, Aurélie Auguste 01/12/2019 Nature Communications
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy Fabrice André 01/12/2019 Annals of Oncology
An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells Caroline Robert, Fabrice André, Shensi Shen, ... 01/12/2019 Nature Communications
Long-term fatigue and cognitive disorders in breast cancer survivors I. Vaz-Luis, Antonio Di Meglio, Melanie Dos Santos 01/12/2019 Cancers
Efficacy of PI3K inhibitors in advanced breast cancer Fabrice André, Monica Arnedos 01/12/2019 Annals of oncology : official journal of the European Society for Medical Oncology
Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non–small-cell lung cancer Emma Pailler, Vincent Faugeroux, Marianne Oulhen, ... 15/11/2019 Clinical Cancer Research
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis Fabrice André, A. R. Ferreira, I. Vaz-Luis, ... 01/11/2019 Annals of oncology : official journal of the European Society for Medical Oncology
EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees† Yohann Loriot 01/11/2019 Annals of oncology : official journal of the European Society for Medical Oncology
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA -mutated, high-grade ovarian cancer, and an update on safety Alexandra Leary 01/11/2019 International Journal of Gynecological Cancer
Risk-based stratification in head and neck mucosal melanoma Caroline Robert, Antoine Moya-Plana 01/10/2019 Oral Oncology
Exploiting DNA repair vulnerabilities with PARP inhibitors to stimulate anti-tumor immunity Sophie Postel-Vinay, Roman M. Chabanon 01/10/2019 Medecine/Sciences
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) Fabrice André, I. Vaz-Luis 01/09/2019 ESMO Open
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research Fabrice André 01/09/2019 Annals of Oncology
EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer Jean Charles Soria, F. Farace 01/08/2019 European Journal of Cancer
Erdafitinib in locally advanced or metastatic urothelial carcinoma Yohann Loriot 25/07/2019 New England Journal of Medicine
ROCK2 inhibition triggers the collective invasion of colorectal adenocarcinomas Olivier Zajac, Joel Raingeaud, Fotine Libanje, ... 15/07/2019 EMBO Journal
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract Yohann Loriot 01/07/2019 European Urology
Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma Caroline Robert, Antoine Moya-Plana, Jean Yves Scoazec, ... 01/07/2019 Cancer Immunology, Immunotherapy
Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies Yohann Loriot 01/07/2019 European Urology Oncology